The companies said their jointly developed Enbrel, administered in pre-filled syringes, is the first biologic to induce a major clinical response in victims of the disease, helping physicians measure improvement over a six-month period. The companies said they also got approval for new data on the treatment's effectiveness to be included in Enbrel labeling.

Full Story:

Related Summaries